News Center

Company news

Media reports

11

2018-01

Having Completed Series C Investment of RMB288 Million, Suzhou Kintor Accelerates the R&D of Innovative Anti-Cancer Drugs

On January 11, 2018, Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor") announced the completion of Series C investment of RMB 288 million. This round of investment was led by Green Pine Capital Partnership, and followed by Orient Securities Capital Investment, Hangzhou Betta Capital, CCB Investment, and Shanghai Broad Resources, etc.

Picture Name

17

2015-07

Suzhou Kintor’s New Anti-Cancer Drug, Proxalutamide, Receives Special Funding for Significant Novel Drugs Development in the “National 13th Five-Year Plan”

Recently, a new-generation AR antagonist, proxalutamide, independently developed by Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor") receives initiation funding for special project of significant novel drugs development in "13th Five-Year plan".

Picture Name
< 1...19202122 > proceed page

Kintor